Key result
3D echocardiography detects a ~4% reduction in EF following cardiotoxic chemotherapy missed by 2D echocardiography.
Why the study?
Anthracyclines pose a high risk for long-term cardiac dysfunction, making early detection crucial to prompt earlier treatment modification.
Does 3D echocardiography improve the early detection of subclinical myocardial dysfunction compared to 2D echocardiography in patients undergoing cardiotoxic chemotherapy?
Observational (n=46)
No
Does 3D echocardiography improve the early detection of subclinical myocardial dysfunction compared to 2D echocardiography in patients undergoing cardiotoxic chemotherapy?
Absolute Event Rate: 3.55% vs 0.67%
p-value: p=<0.001
3D echocardiography is more sensitive than 2D echocardiography for detecting early subclinical left ventricular dysfunction in patients undergoing anthracycline chemotherapy.
May support 3D echocardiography for cardiotoxicity monitoring; hypothesis-generating and requires prospective validation before practice change.
BACKGROUND: Chemotherapy-induced cardiotoxicity constitutes subclinical myocardial dysfunction, arrhythmias, pericarditis, coronary vasospasm, and significant symptomatic heart failure. Anthracyclines pose higher risk for long-term cardiac dysfunction, with increased incidences of morbidity and mortality. Hence, early detection of chemotherapy-induced cardiac dysfunction may prompt an earlier treatment modification. AIM: To evaluate global, longitudinal, radial, and circumferential strain changes in adult patients undergoing anthracycline chemotherapy along with the usefulness of three-dimensional (3D) echocardiography as the new modality over two-dimensional (2D) echocardiography. METHODS: This was a single centre, prospective, observational study that included asymptomatic patients free from any cardiac signs and symptoms attributable to heart failure, who underwent potentially cardiotoxic chemotherapy for malignancy from December 2017 to November 2018 at a tertiary care centre in India. Baseline demographics were recorded, and 2D and 3D echocardiography was performed at baseline and after completion of four cycles of chemotherapy. RESULTS: . Follow-up period from the beginning of doxorubicin therapy was 108 ± 14 days. 9 patients were excluded from the study due to poor 3D images, so data analysis was done only for 46 patients. In 2D echocardiography, only global longitudinal strain (GLS) was observed to be significantly reduced (Δ18.33%; P < 0.001). 2D ejection fraction (EF) did not show significant change (Δ0.67%; P = 0.176), while by 3D echo, EF reduced significantly (Δ3.55%; P < 0.001). 3D global longitudinal (Δ29.19%; P < 0.001), circumferential (Δ30.65%; P < 0.001), area (Δ21.61%; P < 0.001), and radial (Δ29.66%; P < 0.001) strains were observed to be significantly reduced at follow-up. CONCLUSION: Myocardial dysfunction induced by cardiotoxic chemotherapy can be detected earlier by using 2D GLS, 3D volumetric analysis, and 3D strain analysis by calculating global, longitudinal, radial, and circumferential strain changes. 3D echocardiographic assessment seems to be more accurate in picking out small changes in left ventricular functions, but at the cost of slightly poor image quality as compared to the 2D echocardiography. These newer techniques could potentially improve the ability for early detection of subclinical abnormalities of LV function in patients undergoing cardiotoxic chemotherapy and thus early initiation of treatment could be possible.
No takes yet. Share an insight, caveat, or question.
Alam et al. (2019) conducted an observational in Malignancy undergoing cardiotoxic chemotherapy (n=46). 3D echocardiography vs. 2D echocardiography was evaluated on Reduction in ejection fraction (EF) (p=<0.001). 3D echocardiography detected significant reductions in ejection fraction (Δ3.55%; P<0.001) following cardiotoxic chemotherapy, whereas 2D echocardiography did not (Δ0.67%; P=0.176).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: